| abstract |
The present invention relates to the treatment of cardiovascular disorders such as heart failure with retained ejection fraction or reduced ejection fraction heart failure, renal disorders such as chronic renal failure, urological disorders, lung disorders, central nervous system disorders and Fibrotic diseases and other disease symptoms (eg, end organ damage affecting the brain, kidney or heart) for prevention and / or for regulation of cerebral perfusion in the case of demented cerebrovascular conditions, for example The invention relates to stimulants and activators of soluble guanylate cyclase in combination with inhibitors of neutral endopeptidase and / or angiotensin II antagonists for the treatment and / or prophylaxis of and the use thereof. |